Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694600 · ClinicalTrials.gov registry record
Clinical Trial Multi-analyte Blood Test
A clinical trial, sponsored by Helio Genomics.
- Active
- Registry status
- 1,900
- Enrollment target
NCT03694600: Active study, sponsored by Helio Genomics.
NCT03694600 is a clinical trial that is active but no longer recruiting, run by Helio Genomics. The registered enrollment target is 1,900 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694600 is active but no longer recruiting, sponsored by Helio Genomics.
- ACTIVE NOT RECRUITING
- Registry status
- 1,900 participants
- Enrollment target
Study Summary
This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone to ultrasound alone for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
Primary Outcome
The primary objective is to compare the performance (sensitivity and specificity) of the multi-analyte blood test alone to ultrasound alone for the detection of liver cancers within a high-risk population.
Interventions
- DIAGNOSTIC_TEST Multi-analyte blood Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2027-12-30 |
What the registry record for NCT03694600 still lists
NCT03694600 is an observational study that tracks outcomes without assigning an intervention. Its 1,900 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Multi-analyte blood Test is the first listed.
NCT03694600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03694600 about?
NCT03694600 is a clinical study titled "Clinical Trial Multi-analyte Blood Test". This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone to ultrasound alone for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
What is the current status of trial NCT03694600?
This trial is currently active not recruiting. The enrollment target is 1,900 participants. The study started on 2019-02-04. Estimated completion is 2027-12-30.
What interventions are being tested in trial NCT03694600?
The interventions under investigation include: Multi-analyte blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03694600?
This trial is sponsored by Helio Genomics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI